Anthony Cole Gallegos1, Michael James Davis2, Catherine N Tchanque-Fossuo1,3, Kaitlyn West3, Angela Eisentrout-Melton3, Thomas R Peavy4, Roy W Dixon5, Roma P Patel6,7, Sara Evona Dahle1,8, Roslyn Rivkah Isseroff1,3. 1. Department of Dermatology, University of California Davis School of Medicine, Sacramento, California. 2. Department of Surgery, University of California Davis School of Medicine, Sacramento, California. 3. Dermatology Service; Department of Surgery; VA Northern California, Sacramento VA Medical Center, Mather, California. 4. Department of Biological Sciences, California State University, Sacramento, Sacramento, California. 5. Department of Chemistry, California State University, Sacramento, Sacramento, California. 6. Ophthalmology Service; Department of Surgery; VA Northern California, Sacramento VA Medical Center, Mather, California. 7. UC Davis Health System Eye Center, UC Davis School of Medicine, Sacramento, California. 8. Podiatry Section, Department of Surgery; VA Northern California, Sacramento VA Medical Center, Mather, California.
Abstract
Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma. Copyright 2019,
Objective: There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucomapatients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma. Copyright 2019,
Authors: P H Vlasses; L G Ribeiro; H H Rotmensch; J V Bondi; A E Loper; M Hichens; M C Dunlay; R K Ferguson Journal: J Cardiovasc Pharmacol Date: 1985 Mar-Apr Impact factor: 3.105
Authors: Anthony Gallegos; Thomas Peavy; Roy Dixon; Roslyn Rivkah Isseroff Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2018-08-21 Impact factor: 3.205
Authors: Min-Ho Kim; Farzam Gorouhi; Sandra Ramirez; Jennifer L Granick; Barbara A Byrne; Athena M Soulika; Scott I Simon; R Rivkah Isseroff Journal: J Invest Dermatol Date: 2013-10-11 Impact factor: 8.551